Bayer, a leading healthcare product manufacturer, said today it will invest up to 100 million euros ($129.22 million) in the coming five years to establish a research and development (R&D) center in
The need for German pharmaceutical company Bayer to restructure is discussed almost daily in the press. In these reports, the name of one blockbuster always comes up: Xarelto. Its substance patent
Bayer AG, one of the top five hundred enterprises in the world, attaches great importance to its IPR development. In 2009, a small private enterprise in Henan province (China) tried to establish
Recently, Bayer Pharma AG, Bayer AG and Janssen Pharmaceuticals, Inc. filed a complaint in the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. alleging patent
total 1 pages, 4 items